Anavex Life Sciences (Nasdaq: $AVXL) Stock Hub 2026: A Withdrawn European Application, A Chief Executive Terminated For Cause, Two Unfiled Quarterly Reports And A Contested Board

01 What Anavex Is In August 2026

Anavex Life Sciences Corp. is a Nevada corporation headquartered at 630 5th Avenue, 20th Floor, New York, trading
on the Nasdaq Stock Market under $AVXL with Commission file number 001-37606. Its fiscal year ends on September 30.
It is a clinical-stage biopharmaceutical company: it has no approved product, no product revenue, and one compound
that carries the whole business.

That compound is blarcamesine, also written ANAVEX2-73, an orally administered small molecule targeting the
sigma-1 receptor and muscarinic receptors. Three indications are being pursued as of August 2026: early Alzheimer’s
disease, Rett syndrome and Fragile X syndrome. Parkinson’s disease dementia and schizophrenia, both of which appeared
in the company’s own pipeline descriptions through 2025, are no longer among the priorities.

Anything written about Anavex before the spring of 2026 describes a different company. Four things changed between
March and August 2026, and each of them is documented in a filing rather than inferred. On March 25, 2026 the company
withdrew its European marketing authorisation application for blarcamesine. On April 30, 2026 a special committee of
independent directors terminated the employment of chief executive Christopher Missling for cause. Two quarterly
reports, for the periods ended March 31 and June 30, 2026, have not been filed, which put the company out of
compliance with a Nasdaq listing rule. And an activist investor is running a proxy contest to replace the entire
board at the annual meeting of September 24, 2026.

At the same time the balance sheet is the strongest part of the story: cash and cash equivalents of $118.3 million
at June 30, 2026, no debt, and a company statement that this funds operations into mid to late fiscal 2028. The market
capitalisation on August 25, 2026 was approximately $332.8 million at a share price of $3.59.

Each of these threads is traced below against the document it comes from, with dates attached. Where the company
and the challenger describe the same facts differently, both descriptions are given and neither is endorsed.

02 Blarcamesine, And Why It Is Not An Antibody

Blarcamesine is not an anti-amyloid antibody, and that distinction is the whole of the scientific argument. The
approved antibodies in early Alzheimer’s disease, lecanemab and donanemab, clear amyloid plaque and are given
intravenously, with periodic MRI monitoring for amyloid-related imaging abnormalities. Blarcamesine is a once-daily
oral capsule acting on the sigma-1 receptor, a chaperone protein at the interface between the endoplasmic reticulum
and the mitochondria, with a mechanism the company frames around cellular homeostasis and autophagy rather than plaque
removal.

The clinical package rests on one controlled study: ANAVEX2-73-AD-004, a Phase 2b/3 trial in early Alzheimer’s
disease whose top-line results were released in December 2023, presented in full in July 2024 and published in a
peer-reviewed journal in January 2025. That sequence of dates is not in dispute; the activist’s proxy statement cites
exactly the same three milestones.

The company has historically emphasised a precision-medicine element, that SIGMAR1 genotype may predict response,
and the practical advantages of an oral drug with no ARIA risk and no routine imaging requirement. Those are
mechanistic and logistical arguments. They describe why the drug could matter if it works; they are not evidence that
it does, and the regulatory record of the past twelve months is a record of agencies asking for more.

Two supporting studies now sit under a United States investigational new drug application and are required before
any approval in any indication: an absorption, distribution, metabolism and elimination study, referred to as ADME,
and a drug-drug interaction study, referred to as DDI. The company’s position, stated on August 25, 2026, is that the
European assessment report set out these foundational clinical pharmacology and nonclinical requirements clearly, and
that it anticipates the FDA will have the same requirements.

03 The European Chapter, From Encouragement To Withdrawal

The European chapter opened with encouragement and closed with a withdrawal, and the whole of it happened in about
two and a half years.

Anavex submitted its marketing authorisation application for blarcamesine as an add-on therapy in early Alzheimer’s
disease following encouragement from the EMA’s SME Office in October 2023. On November 11, 2025 the company gave its
oral explanation to the Committee for Medicinal Products for Human Use. On November 14, 2025 it disclosed that the
committee had delivered a negative trend vote, and the shares fell by roughly half in a session.

The formal opinion was expected at the December 2025 committee meeting, and the company said at the time that it
intended to request a re-examination, a process that can extend a review by up to four months. That is where the
earlier Merlintrader note on this company stopped, in November 2025, and it is the point at which everything written
then became provisional.

What happened instead: on March 25, 2026 Anavex withdrew the application. The company’s own words,
in the release furnished to the SEC that day, are that the decision followed feedback from the committee indicating
that it would not be in a position to issue a positive opinion for the application at this time. There is no European
approval, no pending European application, and no re-examination in progress.

Two consequences follow, and the company has stated both. The first is that a Phase 3 study in Europe is not being
pursued at this time, though it may be considered later. The second is more useful: the company has completed its
review of the CHMP assessment report and says the report clearly outlined the foundational clinical pharmacology
studies and nonclinical work required for a potential future approval. A rejected application that produces a written
list of what is missing is worth more than a silent one, and the company is explicitly using that list to shape its
American filing.

In June 2026 Anavex received Scientific Advice from the EMA on the design of the proposed Phase 3 study,
ANAVEX2-73-AD-005, covering study population, endpoint hierarchy, treatment duration, statistical framework and
subgroup strategy. That advice is being folded into the discussions the company plans to hold with the FDA.

04 April 30, 2026: The Chief Executive Terminated For Cause

On April 30, 2026 a special committee composed of independent directors terminated the employment of Christopher
Missling, the company’s chief executive since 2013, for cause as that term is defined in his
employment agreement, effective immediately, for, among other things, conduct that the special committee believed was
inconsistent with company policy.

The wording above is quoted from the Form 8-K filed on May 6, 2026 and repeated verbatim in the two late-filing
notifications and in the definitive proxy statement. The company has not published a fuller description of the
conduct, and none is reproduced here. The special committee consists of Jiong Ma, Claus van der Velden, Axel Paeger
and Peter Donhauser.

Two further facts sit in the same filings. The special committee also requested that Missling resign as a member of
the board, and the definitive proxy statement of August 11, 2026 states that he has refused to date. The board, on the
committee’s recommendation, established an executive committee to exercise the power of the board in the management of
the business, with the proxy statement describing Missling as having increasingly served as a distraction to the
proper functioning of the board.

Missling and Steffen Thomas, both current directors, were not nominated for re-election by the executive committee
and are not nominees at the 2026 meeting, though they are expected to continue as directors until their terms expire
at that meeting.

The company’s own risk disclosure of August 25, 2026 lists, among the factors that could cause actual results to
differ, the duration and outcomes of any current or future litigation related to the termination of the former chief
executive and any related matters. A dispute over a for-cause termination of a founder-era chief executive who remains
on the board and has declined to resign is an open legal exposure of unquantified size, and the company says so
itself.

05 The Interim Chief Executive And The Executive Committee

On May 4, 2026 the board appointed Terrie Kellmeyer as interim chief executive officer. Her background is regulatory
and clinical rather than commercial or scientific-founder: senior vice president of clinical development at Anavex
from November 2023 to May 2025, then a senior advisor to the company, with earlier positions as group vice president
of clinical development at Acer Therapeutics, head of global regulatory affairs at Madrigal Pharmaceuticals, and roles
at Intercept, Amylin and Gen-Probe. Her annual base salary was set at $500,000 with an anticipated bonus of 30 per
cent of base.

The disclosure also records that she has been acting as executive vice president, regulatory affairs at Aardvark
Therapeutics since May 2025, a fact stated in the Form 8-K itself.

Her stated priority, in both quarterly releases she has signed, is engagement with the FDA to align on a clear,
data-driven regulatory and clinical development strategy. The word that recurs in her quotes is methodical. In
practical terms the change of approach is visible in what the company is now doing: opening an IND, running the two
clinical pharmacology studies the European regulator asked for, requesting formal meetings, and narrowing to three
indications rather than seven.

Whether that is the right correction or an overcorrection is what the September vote is about, and it is not
settled by anything in the filings.

06 Two Missing Quarterly Reports And A Nasdaq Deficiency

Anavex has not filed a quarterly report since February 9, 2026. Two are outstanding: the Form 10-Q for the quarter
ended March 31, 2026, due May 11, and the Form 10-Q for the quarter ended June 30, 2026, due August 10.

Both late-filing notifications on Form 12b-25 give the same reason, in the same words: until the special committee
and the company complete their review of certain matters related to the termination of Dr. Missling, and the interim
chief executive has had sufficient opportunity to review the report prior to certification, the company cannot
complete its preparation and review without unreasonable effort or expense.

The listing consequence arrived on May 20, 2026, when Nasdaq sent a deficiency notification for non-compliance with
Listing Rule 5250(c)(1), which requires timely filing of all required periodic reports. The notice had no immediate
effect on the listing. On July 20, 2026 the company timely submitted a compliance plan, which was under review by the
Nasdaq staff at the date of that disclosure. If the plan is accepted the staff may grant an extension; if it is not,
the company can request a hearing before an independent panel.

As of August 25, 2026 the company states that it plans to file both outstanding reports in the near term and
continues to work with Nasdaq to fully regain compliance as quickly as possible. Neither report had been filed on
that date.

The practical effect for anyone reading the numbers is direct. The most recent audited or
SEC-filed balance sheet for Anavex is dated December 31, 2025. Everything reported for the March and
June 2026 quarters comes from press releases furnished under Item 2.02, which are expressly not deemed filed for the
purposes of Section 18 of the Exchange Act, and the March figures were additionally labelled preliminary and subject
to completion of closing procedures. Those numbers are used throughout this report because they are the best available
and they come from the company, but they carry a different status from a filed 10-Q.

07 The Proxy Contest: Who Is Challenging, And With How Many Shares

On July 24, 2026 PVG Asset Management Corporation and Patrick S. Adams filed a preliminary proxy statement seeking
to replace the entire Anavex board. The company filed its own preliminary statement on July 31, its definitive
contested proxy on August 11, and the challenger filed a revised preliminary statement on August 18 and additional
soliciting material on August 20.

The PVG slate is six names: Patrick S. Adams, Jason Kolbert, Ralf von Ziegesar, Rene Mora, John Boris and Curtis
Hogue. The board is currently composed of six directors, four of whom are standing for election, alongside two new
nominees put forward by the executive committee. Both sides are therefore contesting all six seats.

The size of the challenger’s own position is the number that frames everything else: the participants in the PVG
solicitation collectively beneficially own 337,663 shares, against 92,696,842 shares outstanding and
entitled to vote. That is approximately 0.36 per cent of the register.

A contest brought from a third of one per cent of the shares is not decided by the challenger’s votes. It is
decided by how the roughly 40 per cent held by institutions splits, by how much of the retail majority votes at all,
and by the recommendations of the proxy advisory firms. Anavex has an unusually large retail base for a company of its
size, and retail turnout in contested elections is historically low and hard to predict.

The mechanics: the meeting is virtual, on September 24, 2026 at 8:30 a.m. Eastern time. The record date is July 31,
2026. The company is soliciting on a WHITE universal proxy card, the challenger on a GOLD one, and under the universal
proxy rules each card lists all candidates from both sides. Proposal 2, ratification of Grant Thornton as auditor for
the fiscal year ending September 30, 2026, is supported by both sides.

08 What The Challenger Argues

What follows is a summary of the arguments made in the PVG Group’s proxy statement of August 18, 2026. They are the
challenger’s assertions, presented as such, and their inclusion here is not an endorsement of any of them.

On pace of development. PVG argues that top-line Phase 2b/3 data came in December 2023, the full
data were presented in July 2024 and published in January 2025, and that little has been accomplished since. It asks
why the board did not direct management to start the Phase 3 study in Alzheimer’s disease that would have been
required even under a conditional European approval.

On the cost of the delay. The statement cites net losses of $47.5 million, $43.0 million and
$46.4 million for the fiscal years ended September 30, 2023, 2024 and 2025. Those three figures check out exactly
against the XBRL data Anavex has filed with the SEC. PVG’s framing is that the losses are significant but small
compared with what it believes three years of an approved and marketed drug would have been worth.

On strategy. PVG asserts that the board has abandoned the genetically defined population approach
and deprioritised the Parkinson’s and schizophrenia programmes, which it believes have significant potential.

On governance and disclosure. The statement calls a 10-Q more than three months late inexcusable,
notes that a second one is now also outstanding, and points to the Nasdaq deficiency and to the annual meeting not
being held in the usual time frame as evidence of what it describes as disorganised oversight. It also criticises the
choice of an outside investor relations firm that it says holds itself out as a real estate specialist.

On the share price. PVG states that the stock trades near multi-year lows and attributes this to
board-initiated key-person turnover and the failure to file. On the market data, $AVXL is down 61.81 per cent over one
year, 55.35 per cent over three years and 81.14 per cent over five, and sits 65.48 per cent below its 52-week high;
it is also up 43.60 per cent over the past month.

09 What The Board Argues

The board’s response, in the release of August 3, 2026 and the stockholder letter of August 17, is framed as a
refreshment of its own: two new independent nominees alongside four incumbents, rather than a defence of the status
quo.

The six nominees put forward by the executive committee are Jiong Ma, independent chair of the board and a general
partner at Phoenix Venture Partners; Peter Donhauser; Axel Paeger, appointed to the board effective February 23, 2026;
Gautam Patel; Adrian Senderowicz; and Claus van der Velden. The proxy statement presents them against a skills matrix
covering independence, chief executive or operating experience, financial and capital allocation experience,
biopharma experience, regulatory experience, scientific and research background, commercialisation and launch
experience, and public company directorship.

The company’s own account of the last four months is one of corrective action taken deliberately: a special
committee that acted on a personnel matter, an executive committee formed to keep the board functioning, an interim
chief executive with three decades of regulatory experience, a narrowing to three indications, an IND opened, and two
required pharmacology studies started. On August 17 it launched a dedicated website, voteanavex.com, and mailed a
letter to shareholders.

The two positions are not symmetrical in what they claim. PVG argues that the board has destroyed value through
inaction and then through disruption. The board argues that the disruption was necessary and that the regulatory
foundation being built now is what was missing before. Both are describing the same eighteen months. Shareholders vote
on September 24.

10 The Alzheimer’s Programme After Europe

The Alzheimer’s programme after Europe is a rebuild rather than a continuation, and the sequence of steps is
documented.

At the end of March 2026, the same month the European application was withdrawn, Anavex opened an investigational
new drug application for early Alzheimer’s disease with the FDA. The IND is what allows clinical studies to be run in
the United States and gives a formal basis for substantive discussions with the agency. On August 25, 2026 the company
said it has submitted all data from its Alzheimer’s disease clinical trials to that newly opened IND.

The company held a Type C meeting with the FDA in November 2025, before the European withdrawal. It is now
combining three inputs, in its own description: the CHMP feedback on the marketing application, the June 2026 EMA
Scientific Advice on the Phase 3 design, and the November 2025 Type C feedback. The stated purpose is to position the
completed studies correctly within an overall development plan and to design a Phase 3 study, ANAVEX2-73-AD-005, for
an Alzheimer’s indication.

The company describes this as a critical step in establishing a solid partnership with the FDA and educating the
agency on its current data package. That phrasing repays attention. A company with a completed Phase 2b/3 trial,
published in a peer-reviewed journal, describing its position as educating the regulator on its data package is
describing a programme at the start of a regulatory conversation, not near the end of one.

No Phase 3 study in Alzheimer’s disease has been initiated, no protocol has been agreed with the FDA, and no date
has been given for either. The scientific advisory board has been, in the company’s words, refreshed and streamlined
to a focused group of Alzheimer’s key opinion leaders and treating physicians.

11 The Two Studies That Have To Come First

Two studies now sit between blarcamesine and any approval anywhere, and they are not efficacy studies.

The ADME study measures absorption, distribution, metabolism and elimination: where the drug goes in the body and
how it leaves. The DDI study measures drug-drug interactions: what happens when blarcamesine is taken alongside other
medicines, which for a drug intended for elderly patients with multiple prescriptions is not a formality. Both are
running in the United States under the Alzheimer’s IND, and the company states they will provide critical support
across all pipeline programmes, not just Alzheimer’s.

Status as of August 25, 2026: the first participant visit has occurred in the ADME study, and the last participant
visit in the DDI study is expected by the end of September, which would complete the clinical conduct of that study.
In the July 30 release the company had said dosing in the DDI study was already underway and that ADME initiation was
anticipated in the third calendar quarter of 2026.

The reason these studies matter more than their subject matter suggests is what the European assessment report
said. The company’s own statement is that the report clearly outlined the foundational clinical pharmacology studies
and nonclinical work required for a potential future approval, and that it anticipates the FDA will have the same
requirements. Read plainly: blarcamesine had a marketing application under review in Europe without this package
complete, and the package is being built now, in 2026, for a compound first taken into clinical trials years earlier.
The company frames the studies as an enabler across the pipeline. They are also the answer to a question that was
asked and not satisfied.

12 Rett Syndrome, And The Paediatric Question

Rett syndrome is a rare X-linked neurodevelopmental disorder, and it is the indication where Anavex holds the most
regulatory scaffolding: the FDA has granted blarcamesine Orphan Drug Designation, Rare Pediatric Disease Designation
and Fast Track Designation for Rett.

The planned study is ANAVEX2-73-RS-005: a Phase 3, randomised, double-blind, placebo-controlled trial in
approximately 170 participants, randomised one to one to blarcamesine or placebo for a 16-week double-blind treatment
period, followed by a safety follow-up, with the option of an open-label extension.

The company is moving forward with an adult study while working with the FDA in parallel on the inclusion of
paediatric patients, and has submitted a formal meeting request to discuss adding them to the approved protocol. It
also plans to meet the Clinical Trials Committee of the International Rett Syndrome Foundation.

The paediatric question is the substance here rather than a procedural detail. Rett syndrome presents in early
childhood; a therapy studied only in adults addresses a fraction of the population and a fraction of the commercial
opportunity, and the Rare Pediatric Disease Designation the company holds is itself oriented to paediatric use.
Running an adult study while negotiating paediatric inclusion is a way of not losing more time, and it is also an
admission that the alignment is not yet in place.

Fragile X syndrome is the third priority and the earliest. The company holds Orphan Drug Designation and expects to
submit the IND in September 2026, supported by what it describes as supportive preclinical and biomarker data and the
absence of any approved therapy. As of August 25, 2026 that IND had not been submitted.

13 What Was Dropped: Parkinson’s And Schizophrenia

What is no longer in the pipeline is as informative as what is.

Through 2025 Anavex described itself as working on Alzheimer’s disease, Parkinson’s disease dementia, Rett syndrome
and schizophrenia, with ANAVEX3-71 as a second clinical asset. The July 30, 2026 release states that the strategy now
concentrates resources on blarcamesine across three indications: early Alzheimer’s disease and Rett syndrome, where
the clinical and regulatory foundation is most advanced, and Fragile X.

The reduction in research spending shows where the programmes went. Research and development expense in the second
fiscal quarter of 2026 was $4.2 million against $9.9 million a year earlier, and the company attributes the decrease
primarily to the completion of the ANAVEX3-71 clinical trial in schizophrenia and to lower clinical manufacturing
activity.

The challenger’s proxy statement treats this narrowing as one of its principal criticisms, asserting that the board
has abandoned the genetically defined population approach and deprioritised Parkinson’s and schizophrenia, which it
believes have tremendous potential. The company’s position is that it is prioritising the programmes it believes have
the greatest chance of regulatory success.

Both descriptions are accurate as descriptions. A company with $118.3 million and no revenue that runs four
indications at once funds none of them properly; a company that narrows to three has fewer chances of an unexpected
win. Which risk is the right one to take is precisely what is being voted on in September, and neither position can be
settled by reading the filings.

14 The Third Fiscal Quarter Of 2026 In Numbers

The third fiscal quarter of 2026, for the three months ended June 30, 2026, as reported in the press release
furnished to the SEC on August 25, 2026. No Form 10-Q has been filed for this period.

Cash and cash equivalents were $118.3 million at June 30, 2026, against $102.6 million at fiscal year end on
September 30, 2025. General and administrative expenses were a net recovery of $(2.0) million, against an expense of
$4.5 million in the third fiscal quarter of 2025. Research and development expenses were a net recovery of
$(4.7) million, against $10.0 million a year earlier. Net income for the quarter was $7.8 million, or $0.08 per share,
against a net loss of $13.2 million, or $0.16 per share, in the same quarter of 2025.

For the second fiscal quarter, ended March 31, 2026, the preliminary figures released on July 30, 2026 were: cash
of $127.4 million, general and administrative expenses of $2.3 million against $2.6 million a year earlier, research
and development expenses of $4.2 million against $9.9 million, and a net loss of $5.3 million, or $0.06 per share,
against $11.2 million, or $0.13 per share.

The prior three fiscal years, from filed annual reports: net losses of $47.5 million for the year ended
September 30, 2023, $43.0 million for 2024 and $46.4 million for 2025.

15 The Profit That Is Not A Profit

A clinical-stage company with no product reporting net income of $7.8 million requires an explanation, and the
company gives it in the same release.

The quarter contains a reversal of $7.5 million of stock-based compensation expense within general
and administrative, and a reversal of $9.9 million within research and development, both associated
with the termination of employees, primarily the former chief executive. That is $17.4 million of previously recorded
expense taken back out.

The accounting is standard. Share-based awards are expensed over a vesting period on the assumption the recipient
stays to vest them; when employment ends before vesting, the expense recognised for the unvested portion is reversed.
It is a non-cash entry in both directions.

What it means for reading the quarter: the $7.8 million of net income is not a profit, it is the accounting
consequence of the April 30 termination and the departures around it. Strip the $17.4 million reversal out and the
quarter runs at an underlying operating loss in the region of $9 to $10 million, consistent with the $5.3 million loss
of the previous quarter and with a company burning roughly $40 to $46 million a year.

The cash statement confirms it independently, and cash does not reverse. The balance went from $127.4 million at
March 31 to $118.3 million at June 30: $9.1 million consumed in the quarter, in a period reporting
positive net income. The two facts are not in conflict; they are the same fact seen from two sides.

16 Cash, Burn And The Runway To 2028

Cash of $118.3 million at June 30, 2026 against no debt is the reason this company is not in an existential
position despite everything described above, and the figures behind it are set out here with the same precision as the problems.

The company’s runway statement, repeated in both quarterly releases, is that the balance is expected to fund
operations into mid to late fiscal 2028. Anavex’s fiscal year ends in September, so mid to late fiscal 2028 means
roughly the first half of calendar 2028, on the order of seven to eight quarters from the June 2026 balance sheet
date.

That statement is arithmetically consistent with the burn. Cash consumption of
$9.1 million in the June quarter annualises to roughly $36 million; $118.3 million at that rate is more than three
years, and at the historical $43 to $47 million annual loss rate it is about two and a half. The company’s own
guidance is therefore conservative relative to the recent burn and roughly in line with the historical one. Nothing in
the runway statement requires revenue, a partnership or a raise, because there is no revenue to forecast.

Balance sheet quality supports it. The June 30, 2026 balance sheet in the company’s release shows total assets of
$120.1 million, all of it current, against total current liabilities of $7.7 million made up of $3.7 million of
accounts payable and $4.0 million of accrued liabilities. There are no other liabilities at all: total liabilities and
total current liabilities are the same $7.7 million figure, which gives a current ratio of 15.6 and confirms the
absence of borrowings. Stockholders’ equity was $112.4 million against an accumulated deficit of $385.6 million and
additional paid-in capital of $498.0 million, the arithmetic of a company that has raised roughly half a billion
dollars over its life and spent most of it.

The qualification is the one that runs through this whole report. The last balance sheet inside a filed quarterly
report is dated December 31, 2025 and showed $131.7 million. The $127.4 million and $118.3 million figures come from
press releases, the first of them expressly preliminary.

17 How The Cash Came Back: The December 2025 Issuance

The cash did not simply decline. It fell for four consecutive quarters, from $132.2 million in September 2024 to
$101.2 million in June 2025, recovered slightly to $102.6 million at fiscal year end, and then rose by $29.2 million
in the quarter ended December 31, 2025.

A clinical-stage company with no revenue does not generate $29 million in a quarter. The share count answers the
question: 86,668,521 shares outstanding at September 30, 2025 and 92,671,758 at December 31, 2025, an increase of
approximately 6.0 million shares in three months.

The timing is the substance. The CHMP negative trend vote was disclosed on November 14, 2025 and
the shares fell by roughly half. The equity was sold into the quarter containing that fall. Whatever the mechanism and
the average price, the effect is that the balance sheet now funding the company through 2028 was substantially
refilled after the worst news it had received.

Since then the issuance has stopped. From 92,671,758 shares at December 31, 2025 to 92,696,842 at the July 31, 2026
record date, the count moved by roughly 25,000 shares in seven months. A company that is not selling stock at $3.59
with $118.3 million in the bank and no near-term data event is behaving consistently with its own runway statement.
Whether that restraint survives a Phase 3 Alzheimer’s programme, once one is designed and costed, is a separate
question with no answer in the filings.

18 Market Snapshot And What Three Numbers Mean

Market data below was read from Finviz Elite on August 25, 2026, during a session in which the stock rose 15.43 per
cent on the third-quarter release. Every figure derived from a price changes continuously.

Three items in that table carry more weight than the rest.

Short interest at 16.06 per cent of the float is high in absolute terms and is the mechanical
explanation for a 15 per cent move on a quarterly release with no clinical content. On a float of 89.81 million shares
against average daily volume of 1.16 million, the short position represents roughly twelve days of average trading.
Moves in both directions are amplified by that structure.

Institutional ownership at 40.17 per cent against insider ownership at 3.12 per cent is the
arithmetic of the September vote, set out in the ownership chart above. Neither side of the proxy contest controls
anything close to a majority.

The $20.00 aggregate price target shown by Finviz is a mechanical average of published sell-side
targets and sits at roughly 5.6 times the current price. The individual targets, their dates and whether they have
been revised since the European withdrawal and the chief executive’s departure were not verified against the source
notes for this report, which are not publicly available. It is recorded because it is what the aggregator publishes,
and a five-fold gap between an aggregate target and a market price usually means the targets are stale, the market is
pricing something the models do not, or both. No view is offered here on which.

The performance table is its own summary: down 61.81 per cent over one year, down 55.35 per cent over three, down
81.14 per cent over five, up 14.33 per cent over ten, and up 43.60 per cent in the last month.

19 Retail Sentiment On Stocktwits

The $AVXL stream on Stocktwits had 23,996 watchers on August 25, 2026, which makes it one of the most followed
small-capitalisation biotechnology symbols on the platform and puts it in a different category from the thinly
discussed names where the sentiment ratio is computed on one or two messages.

The reading that stands out is not the level but the stability. Across the month to August 25 the bullish share of
sentiment-tagged messages never fell below roughly 85 per cent, and it spent most of the period between 90 and
97 per cent. That period contains a missed quarterly filing, a Nasdaq compliance plan submitted under a deficiency
notice, and an activist campaign to remove the entire board.

A retail base that stays above 90 per cent bullish through that sequence is a description of conviction, not of
information. It is also a structural fact about this particular shareholder register: a company whose retail majority
holds through a 62 per cent annual decline is a company where a proxy vote turns on turnout as much as on persuasion,
and where the shares can move violently on sentiment alone given a 16 per cent short float.

These are self-reported opinions from retail traders and non-professional investors on a public message board. They
are not analyst research, they are not verified, the users posting them may hold positions, and nothing in them should
be read as a forecast or as a reason to act.

20 The Catalyst Map

Dated and undated items, separated. Everything below comes from the company’s own statements or from the proxy
filings, with the source date attached; none of it is a Merlintrader forecast.

Two items that dominated the previous version of this page have closed. The European marketing authorisation
application was withdrawn on March 25, 2026, so there is no CHMP re-examination pending and no European decision to
wait for. The question of who runs the company was answered on April 30, 2026, at least on an interim basis.

What the calendar does not contain is any clinical readout. There is no efficacy data event scheduled for
blarcamesine in any indication, in any geography, at any date. The nearest thing to a binary event in the next twelve
months is a shareholder vote.

21 Risks And Red Flags

There is no approved product and no revenue, and the only controlled efficacy dataset is three years
old. The Phase 2b/3 read out in December 2023. Since then the European regulator declined to move to a
positive opinion and the application was withdrawn. No Phase 3 has started in any indication.

Two required quarterly reports have not been filed. The most recent SEC-filed balance sheet is
dated December 31, 2025. The figures for March and June 2026 come from press releases furnished under Item 2.02, which
are expressly not deemed filed, and the March set was labelled preliminary. Anyone modelling this company is
modelling unaudited, unfiled numbers.

The listing is under a live deficiency. Nasdaq issued a notice on May 20, 2026 under Listing Rule
5250(c)(1). A compliance plan was submitted on July 20 and was under review. If it is rejected the company must
request a hearing before an independent panel.

The chief executive of twelve years was terminated for cause and remains on the board. The special committee asked
Missling to resign as a director and, as of August 11, 2026, he had refused. The company itself lists litigation
related to the termination among its risk factors, with no quantification.

The entire board is being contested. A vote on September 24, 2026 can replace all six directors.
Neither outcome is a resolution: a challenger slate would take over a company whose regulatory strategy is mid-flight,
and an incumbent win leaves a shareholder base that has just seen a campaign against it.

The regulatory foundation is being built now, not being completed. The ADME and DDI studies that
the European assessment report identified as required were started in 2026. The company expects the FDA to have the
same requirements.

Dilution history and a short position that cuts both ways. Share count rose by about 6.0 million,
or seven per cent, in the quarter following the November 2025 fall. Short interest is 16.06 per cent of the float,
roughly twelve days of average volume, which amplifies moves in both directions.

The reported profit is not one. Net income of $7.8 million in the June quarter is the reversal of
$17.4 million of stock-based compensation on employee departures. Cash fell by $9.1 million in the same quarter.

22 Merlintrader Health Score

The Merlintrader Health Score is a one-to-five reading of how robust a company’s position looks over the next
twelve to eighteen months, built from five weighted pillars. It describes financial and operational fragility. It is
not a rating, not a recommendation, and it says nothing about whether the shares are cheap or expensive.

Weighted result: 2.8 out of 5. The arithmetic: (4 × 0.30) + (2 × 0.30) + (3 × 0.20)
+ (3 × 0.10) + (1 × 0.10) = 2.80. A balance sheet that buys time, against an execution record that is the
reason the time is needed.

23 Scenarios

Three descriptive paths, each traced from figures already in this report. They are not probabilities, not forecasts
and not recommendations, and the list is not exhaustive.

The rebuild holds. The two outstanding 10-Q filings are made, Nasdaq compliance is regained, the
Fragile X IND goes in, the DDI study completes, and the FDA meetings produce an agreed Phase 3 protocol in Alzheimer’s
disease and paediatric inclusion in Rett. In that case the company reaches 2028 with $118.3 million, three defined
programmes and a regulatory package built to the standard the European report set out. Nothing in that path produces
efficacy data before the end of the decade, and the equity would be re-rated on process rather than on results.

The vote changes the company. If the PVG slate wins on September 24, six new directors take over a
company mid-strategy. The challenger’s stated criticism is that the board was too slow to start a Phase 3 and has
narrowed the pipeline too far, which implies a faster and broader programme funded from the same $118.3 million. A
change of control of the board would also reopen questions about the interim chief executive, the terminated
executive’s status and the pending strategy, in a company that has already lost four months to a governance dispute.

The overhang persists. The filings slip further, the Nasdaq plan is rejected and a hearing is
required, or litigation over the termination becomes material. In that path the balance sheet still funds operations,
which is the point of having it, but the discount applied to the equity has a governance component that no clinical
progress removes quickly.

Across all three, the constant is that the science does not move. There is no scheduled efficacy readout for
blarcamesine in Alzheimer’s disease, Rett syndrome or Fragile X. What changes in the next twelve months is who runs
the company, whether it files its accounts, and whether the FDA agrees to a protocol.

24 Bottom Line

Anavex in August 2026 is a company with a strong balance sheet, a contested board, two unfiled quarterly reports
and no scheduled clinical data.

The financial position is genuinely solid and stated plainly: $118.3 million of cash at June 30, 2026, no debt of
any kind, a current ratio above eighteen, and a runway statement into mid to late fiscal 2028 that is consistent with
a burn of roughly $36 to $46 million a year. Most of that cash came from selling about 6.0 million shares in the
quarter that followed the November 2025 European setback, and the issuance has been essentially dormant since.

The regulatory position is a restart. The European application was withdrawn on March 25, 2026 after the committee
indicated it could not issue a positive opinion. What the company took from that process is a written list of what a
future approval requires, and the two clinical pharmacology studies on that list are running now. The American path
begins with an IND opened at the end of March 2026 and a set of meetings that have not yet produced an agreed Phase 3
protocol.

The governance position is unresolved. A chief executive of twelve years was terminated for cause on April 30,
2026, has declined to resign from the board, and is not standing for re-election. Two quarterly reports are late and
the listing carries a live deficiency notice. An activist holding 0.36 per cent of the shares is asking shareholders
to replace all six directors on September 24.

Every figure in this report carries the date it was true, and two of the most important ones, the March and June
2026 balance sheets, come from press releases rather than from filed reports. The next fixed point is the vote.

Related Research On Merlintrader

• AC Immune ($ACIU) — another company working outside the anti-amyloid antibody consensus in Alzheimer’s disease, with its own regulatory and funding profile.
• RenovoRx ($RNXT) Stock Hub 2026 — a small-capitalisation company whose cash position is measured against a single Phase III readout, the same structural question in oncology.
• Biomea Fusion ($BMEA) Stock Hub 2026 — a fully enrolled pivotal trial and a balance sheet measured against it.
• Top Ten Biotech Stocks Right Now — the names we are following most closely, updated regularly.